MCP-1 expression in PTC may stimulate the aggressive behavior of this tumor or it may be a marker for aggressive behavior. Previous reports with non-thyroid tumor cells favor the hypothesis that MCP-1 expression promotes aggressive behavior in PTC.

No abstract

Determining whether lymph node metastasis exists could be useful for predicting recurrence in patients who have undergone curative resection of PTC.

Background/Aim: Matrix-producing breast carcinoma (MPBC) is a rare and usually aggressive triplenegative breast cancer (TNBC). In the present report, we determined the drug sensitivity for a triple-negative MPBC using a patient-derived orthotopic xenograft (PDOX) model. Materials and Methods: The PDOX model was established in the left 2 nd mammary by surgical orthotopic implantation (SOI). MPBC PDOX models were randomized into 4 groups (6 mice per group) when the tumor volume became 80 mm 3 : G1, control group; G2, cisplatinum group [intraperitoneal (i.p.) injection, weekly, for 2 weeks]; G3, paclitaxel group (i.p., weekly, for 2 weeks); G4, eribulin group [intravenous (i.v.) injection, weekly, for 2 weeks]. All mice were sacrificed on day 15. Tumor volume and body weight were measured one time per week. Results: The MPBC PDOX model was resistant to cisplatinum (p=0.800). Paclitaxel suppressed tumor growth compared to the control group (p=0.009). However, only eribulin regressed the tumor (p=0.001). Conclusion: Eribulin has clinical potential for triple-negative MPBC patients.Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer (1, 2). TNBC is defined by a lack of estrogen receptor (ER), progesterone receptor (PgR), as well as lack of amplification of human epidermal growth factor receptor 2 (HER-2) (1, 2). Approximately 15-20% of all diagnosed breast cancer cases are TNBC (1, 2). TNBCs often become resistant to standard chemotherapy used against them. Therefore, clinical outcomes for patients with metastatic TNBC (mTNBC) indicate a poor prognosis (3).Matrix-producing breast carcinoma (MPBC) is a rare and specialized histological type of metaplastic carcinoma (4). MPBC is usually TNBC. MPBC is an invasive breast carcinoma with direct transition to a cartilaginous or osseous matrix having no intervening spindle-cell component (5,6). Therefore, this tumor should be initially treated with chemotherapy. Although 2475This article is freely accessible online.

Background/Aim: Matrix-producing breast carcinoma (MPBC) is a rare and usually aggressive triplenegative breast cancer (TNBC). In this study, we determined drug sensitivity for a triple-negative MPBC, without BRCA mutations, in a patient-derived orthotopic xenograft (PDOX) model. Materials and Methods: The MPBC PDOX model was established in the left 2 nd mammary gland of nude mouse by implantation of the patient tumor using surgical orthotopic implantation (SOI). We randomized MPBC PDOX mice into 5 groups (n=5 mice/per treatment group) when the tumor volume reached 80 mm 3 : G1, control-no treatment; G2, bevacizumab [intra-peritoneal (i.p.), weekly, for 2 weeks]; G3, vinorelbine (i.p., weekly, for 2 weeks); G4, olaparib (oral., daily, for 2 weeks); G5, eribulin [intravenous (i.v.), weekly, for 2 weeks]. The mice in each treatment group were sacrificed on day 15. Tumor volume and body weight were measured once/week. Results: The MPBC PDOX model was resistant to olaparib (p=0.22). The MPBC PDOX model treated with bevacizumab and vinorelbine showed significantly suppressed tumor growth compared to the untreated group (p=0.005 and 0.002, respectively). However, only eribulin regressed the tumor (p=0.0001). Eribulin was more effective than olaparib (p=0.0001), bevacizumab (p=0.0025) and vinorelbine (p=0.0061). Conclusion: Eribulin has clinical potential as treatment for triple-negative MPBC patients that are resistant to a PARP inhibitor such as olaparib.Triple-negative breast cancer (TNBC) lacks expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) protein.Approximately 15 to 20% of all breast cancers are TNBC (1, 2). TNBC is a highly aggressive breast cancer with frequent recurrence and metastasis, and a higher mortality rate compared to other types of breast cancer (3). Furthermore, the 2509